Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.70 |
| ▸ | KDR | P35968 | 3/20 | 0.70 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.70 |
| ▸ | TTK | P33981 | 3/20 | 0.44 |
| ▸ | EGFR | P00533 | 4/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16514346 | 0.91 | FGFR1 (0.71) | FGFR1KDRFGFR2TTKEGFR | |
| SCHEMBL18527557 | 0.85 | FGFR1 (0.63) | FGFR1KDRFGFR2TTKEGFR | |
| SCHEMBL16513545 | 0.82 | FGFR1 (1.00) | FGFR1KDRFGFR2EGFRJAK3 | |
| SCHEMBL18400948 | 0.81 | FGFR1 (0.83) | FGFR1KDRFGFR2TTKEGFR | |
| SCHEMBL20807734 | 0.81 | FGFR1 (0.77) | FGFR1KDRFGFR2TTKEGFR | |
| Fumaric Acid SCHEMBL16515012 | 0.81 | FGFR1 (0.93) | FGFR1KDRFGFR2TTKEGFR | |
| Maleic Acid SCHEMBL16515010 | 0.81 | FGFR1 (0.93) | FGFR1KDRFGFR2TTKEGFR | |
| SCHEMBL18527562 | 0.81 | FGFR2 (0.57) | FGFR1KDRFGFR2TTKEGFR | |
| SCHEMBL18527537 | 0.81 | TTK (0.60) | FGFR1KDRFGFR2TTKEGFR | |
| SCHEMBL18527529 | 0.81 | FGFR1 (0.57) | FGFR1KDRFGFR2TTKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10653701-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2020-05-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10653701-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | FGFR1 1078/4885KDR 950/4885FGFR2 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.